A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Dalantercept (Primary) ; Axitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DART
- Sponsors Acceleron Pharma
- 14 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2017.
- 14 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2017 Primary endpoint (Part 2: Progression free survival (PFS) has not been met, according to an Acceleron Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History